Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1

Conditions

Smoldering Multiple Myeloma 2Prostatic Neoplasms 2Monoclonal Gammopathy of Undetermined Significance 2Thrombocythemia, Essential 1Stomach Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Neurofibromatosis 1 1Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Gastritis, Atrophic 1

Interventions

Dexamethasone 116daratumumab 68Lenalidomide 67Bortezomib 55pomalidomide 45carfilzomib 40Cyclophosphamide 33Calcium Dobesilate 32Specimen Handling 30Biopsy 28Magnetic Resonance Spectroscopy 25isatuximab 20belantamab mafodotin 20talquetamab 17iberdomide 17fludarabine 17Melphalan 15dexamethasone acetate 14dexamethasone 21-phosphate 14auricularum 14fludarabine phosphate 11selinexor 10elotuzumab 10tocilizumab 9X-Rays 8Nivolumab 8trametinib 7Sirolimus 7Whole-Body Irradiation 6Mycophenolic Acid 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × Curcumin × 90 days × Clear all
NCT04731844 2026-05-12

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer

University of Rochester

Phase 2 Completed
30 enrolled 13 charts
GenitourinaryPlasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡